Hairy cell leukemia: Past, present and future

Best Practice and Research: Clinical Haematology

Volumn 28, Issue 4, 2015, Pages 269-272

  Getta, Bartlomiej M ^a   Park, Jae H ^a,b   Tallman, Martin S ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

BRAF; Hairy cell leukemia; Vemurafenib

Indexed keywords

B LYMPHOCYTE RECEPTOR; B RAF KINASE; CLADRIBINE; DABRAFENIB; IBRUTINIB; MOXETUMOMAB PASUDOTOX; PENTOSTATIN; RITUXIMAB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMMUNOTOXIN; INDOLE DERIVATIVE; SULFONAMIDE;

ARTICLE; GENE EXPRESSION; GENE MUTATION; HAIRY CELL LEUKEMIA; HEMATOPOIETIC STEM CELL; HUMAN; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; DISEASE MANAGEMENT; DRUG EFFECTS; GENETICS; HISTORY; IMMUNOLOGY; LEUKEMIA, HAIRY CELL; MORTALITY; MUTATION; PATHOLOGY; REMISSION; SPLENECTOMY; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CLADRIBINE; DISEASE MANAGEMENT; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOTOXINS; INDOLES; LEUKEMIA, HAIRY CELL; MUTATION; PENTOSTATIN; PROTO-ONCOGENE PROTEINS B-RAF; REMISSION INDUCTION; RITUXIMAB; SPLENECTOMY; SULFONAMIDES; SURVIVAL ANALYSIS;

EID: 84952314340     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2015.10.015     Document Type: Review

References (28)

1. L.M. Morton, S.S. Wang, S.S. Devesa, P. Hartge, D.D. Weisenburger, and M.S. Linet Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 Blood 107 1 2006 265 276
2. B.A. Bouroncle, B.K. Wiseman, and C.A. Doan Leukemic reticuloendotheliosis Blood 13 7 1958 609 630
3. E. Tiacci, V. Trifonov, G. Schiavoni, A. Holmes, W. Kern, M.P. Martelli, and et al. BRAF mutations in hairy-cell leukemia N Engl J Med 364 24 2011 2305 2315
4. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, and et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 26 2011 2507 2516
5. J.R. Quesada, J. Reuben, J.T. Manning, E.M. Hersh, and J.U. Gutterman Alpha interferon for induction of remission in hairy-cell leukemia N Engl J Med 310 1 1984 15 18
6. L.D. Piro, C.J. Carrera, D.A. Carson, and E. Beutler Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine N Engl J Med 322 16 1990 1117 1121
7. M. Else, C.E. Dearden, E. Matutes, J. Garcia-Talavera, A.Z. Rohatiner, S.A. Johnson, and et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis Br J Haematol 145 6 2009 733 740
8. G.R. Goodman, C. Burian, J.A. Koziol, and A. Saven Extended follow-up of patients with hairy cell leukemia after treatment with cladribine J Clin Oncol 21 5 2003 891 896
9. M.S. Tallman, D. Hakimian, K.J. Kopecky, S. Wheaton, E. Wollins, K. Foucar, and et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse Clin Cancer Res 5 7 1999 1665 1670
10. M. Lopez Rubio, C. Da Silva, J. Loscertales, C. Seri, P. Baltasar, E. Colado, and et al. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC) Leuk Lymphoma 55 5 2014 1007 1012
11. J.E. Sausville, R.G. Salloum, L. Sorbara, D.W. Kingma, M. Raffeld, R.J. Kreitman, and et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene Am J Clin Pathol 119 2 2003 213 217
12. E. Tiacci, J.H. Park, L. De Carolis, S.S. Chung, A. Broccoli, S. Scott, and et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia N Engl J Med 2015
13. J.H. Park, and M.S. Tallman Left behind: should minimal residual disease be treated in hairy cell leukemia? Leuk Lymphoma 55 5 2014 971 972
14. F. Forconi, E. Sozzi, E. Cencini, F. Zaja, T. Intermesoli, C. Stelitano, and et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior Blood 114 21 2009 4696 4702
15. T. Robak, E. Matutes, D. Catovsky, P.L. Zinzani, and C. Buske Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger Ann Oncol 26 Suppl. 5 2015 v100 v107
16. M. Else, C.E. Dearden, E. Matutes, F. Forconi, F. Lauria, H. Ahmad, and et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence Leuk Lymphoma 52 Suppl. 2 2011 75 78
17. R.J. Kreitman, M. Stetler-Stevenson, I. Margulies, P. Noel, D.J. Fitzgerald, W.H. Wilson, and et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia J Clin Oncol 27 18 2009 2983 2990
18. R.J. Kreitman, M.S. Tallman, T. Robak, S. Coutre, W.H. Wilson, M. Stetler-Stevenson, and et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia J Clin Oncol 30 15 2012 1822 1828
19. D.H. Robbins, I. Margulies, M. Stetler-Stevenson, and R.J. Kreitman Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2) Clin Cancer Res 6 2 2000 693 700
20. M. Sivina, R.J. Kreitman, E. Arons, F. Ravandi, and J.A. Burger The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach Br J Haematol 166 2 2014 177 188
21. Jeffrey A. Jones, L.A. Farhad Ravandi, Robert J. Kreitman, Charles Schiffter, Timothy Cal, Gerard Lozanski, and et al. Safety and efficacy of the bruton tyrosine kinase inhibitor ibrutinib in patients with hairy cell leukemia: interim resuls of a phase 2 study 2015
22. V. Pettirossi, A. Santi, E. Imperi, G. Russo, A. Pucciarini, B. Bigerna, and et al. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity Blood 125 8 2015 1207 1216
23. S. Dietrich, H. Glimm, M. Andrulis, C. von Kalle, A.D. Ho, and T. Zenz BRAF inhibition in refractory hairy-cell leukemia N Engl J Med 366 21 2012 2038 2040
24. S. Tschernitz, L. Flossbach, M. Bonengel, S. Roth, A. Rosenwald, and E. Geissinger Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias Br J Haematol 165 4 2014 529 533
25. L. Xi, E. Arons, W. Navarro, K.R. Calvo, M. Stetler-Stevenson, M. Raffeld, and et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation Blood 119 14 2012 3330 3332
26. E. Arons, and R.J. Kreitman Molecular variant of hairy cell leukemia with poor prognosis Leuk Lymphoma 52 Suppl. 2 2011 99 102
27. J.J. Waterfall, E. Arons, R.L. Walker, M. Pineda, L. Roth, J.K. Killian, and et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias Nat Genet 46 1 2014 8 10
28. S. Dietrich, J. Hullein, S.C. Lee, B. Hutter, D. Gonzalez, S. Jayne, and et al. Recurrent CDKN1B (p27) mutations in hairy cell leukemia Blood 126 8 2015 1005 1008